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Abstract 1 
Purpose: To examine the association between characteristics of Stargardt disease and visual 2 
acuity (VA), to estimate the longitudinal rate of VA loss, and identify risk factors for VA loss. 3 
Design: Retrospective, multi-center cohort study. 4 
Participants: 176 patients (332 eyes) with molecularly and clinically confirmed Stargardt 5 
disease enrolled from the USA and Europe.  6 
Methods: Standardized data report forms were used to collect retrospective data on 7 
participants’ characteristics and best-corrected or presenting VA from medical charts. Linear 8 
models with generalized estimating equations were used to estimate the cross-sectional 9 
associations, and linear mixed effects models were used to estimate the longitudinal VA loss.  10 
Main Outcome Measures: Yearly change in visual acuity.  11 
Results: The median duration of observation was 3.6 years. At baseline, older age of 12 
symptom onset was associated with better VA, and a longer duration of symptoms with 13 
worse VA. Longitudinal analysis estimated an average of 0.3 lines loss (p<0.0001) per year 14 
overall, but the rate varied according to baseline VA: (i) eyes with baseline VA better than or 15 
equal to 20/25 (N=53) declined at a rate of ~1.0 line per year; (ii) eyes with VA between 16 
20/25 and 20/70 (N=65) declined at a rate of ~0.9 lines per year; (iii) eyes with VA between 17 
20/70 and 20/200 (N=163) declined at a rate of 0.2 lines per year; and (iv) eyes with VA 18 
worse than 20/200 (n=49), improved at a rate of 0.5 lines per year. Older age of onset was 19 
associated with slower VA loss: patients with onset age >30 years showed 0.4 lines slower 20 
change of VA per year (p=0.01) compared to patients with onset ≤14 years. 21 
Conclusion: Given the overall slow rate of VA loss, VA is unlikely to be a sensitive outcome 22 
measure for treatment trials of Stargardt disease. However, given the faster decline in 23 
younger patients and those with no or mild visual impairment, VA may be a potential 24 
outcome measure for trials targeting such subgroups of patients. These observations will 25 
need to be assessed in a prospective study bearing in mind the inherent limitations of 26 
retrospective datasets. 27 
28 
 5 
Introduction 29 
Stargardt macular dystrophy (STGD1; OMIM: 248200) is the most common macular 30 
dystrophy with a prevalence of 10-12.5 per 100,000 persons,1 and is inherited as an 31 
autosomal recessive trait.2 It is characterized by the appearance of yellowish-white lesions 32 
called fundus flecks at the level of the retinal pigment epithelium (RPE) and by the 33 
development of atrophic lesions. Patients with STGD1 experience progressive impairment of 34 
visual acuity which often begins in the first or second decade of life, but some patients may 35 
maintain good VA until the fourth or fifth decade of life.3 Currently there is no approved 36 
treatment for the disease, with on-going phase I/II clinical trials based on gene, stem cell, 37 
and pharmacological therapy.  38 
 39 
There are limited data documenting the rate of change of visual acuity (VA) in STGD1.  40 
Several studies have reported average VA measured at two study visits,4-6 these analyses 41 
however did not take into consideration the variable length of follow-up of the study 42 
participants. Rotenstreich et al. estimated the time to reach VA of 20/200 and its association 43 
with age among participants with VA of 20/40 or better, or VA between 20/50-20/100, at 44 
their first study visit.7 Oh et. al. compared the time to vision loss of 20/200 VA among 45 
different clinical phenotypes.8 More recently, the longitudinal analysis from Testa et al, 9 46 
estimated the yearly progression rate of best corrected VA in STGD1 patients with an age of 47 
onset younger than 30 years.    48 
 49 
To better understand visual function loss in STGD1 and to help assess the appropriateness of 50 
VA as an outcome measure for future treatment trials, we analyzed data from the 51 
retrospective multi-center study on “the natural history of the Progression of Atrophy 52 
 6 
Secondary to Stargardt Disease (ProgStar)“. Our specific purposes were to examine the 53 
cross-sectional relationship between participant demographic, clinical characteristics and 54 
baseline VA, to estimate the yearly rate of VA loss using the longitudinal data, and to identify 55 
participant demographic and clinical characteristics associated with yearly VA change rate. 56 
We identified that the rate of VA loss in the entire cohort was too slow to be an effective 57 
clinical trial outcome measure. However, a faster decline in younger patients and those with 58 
no or mild visual impairment at baseline, suggests that VA may be a potential end-point in 59 
these patient subgroups, and is worthy of assessment in a prospective study bearing in mind 60 
the inherent biases of retrospective data. 61 
 62 
Participants and Methods 63 
Data for this analysis are derived from the retrospective ProgStar study which has been 64 
described in detail elsewhere.10 In brief, from March of 2013 to December of 2014, eligible 65 
participants were identified and enrolled through retrospective review of medical charts at 66 
nine participating sites, including six sites from the United States, and one site each from the 67 
United Kingdom, France and Germany. Inclusion criteria were:10 (1) presence of at least one 68 
well-demarcated area of atrophy with a minimum diameter of 300 µm, with the total area of 69 
all atrophic lesions being less than or equal to 12 mm2 at the most recent visit; (2) presence 70 
of at least two likely disease-causing variants in ABCA4, or one likely disease-causing variant 71 
associated with at least one eye with flecks at the level of the RPE typical for STGD1; (3) 72 
sufficient quality of images and/or psychophysical tests; (4) age at least six years at the most 73 
recent visit; (5) follow-up for at least two visits over a period of at least 24 months, up to 60 74 
months between single visits, and must have had at least one test of the following 75 
completed at each visit for the same eye(s): FAF obtained with a Heidelberg Engineering® 76 
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instrument (e.g. HRA2) and/or SD-OCT obtained with the Heidelberg® Spectralis and/or MP 77 
obtained with the Nidek® MP-1 78 
Exclusion criteria were: (1) presence of ocular disease in either eye that may confound 79 
assessment of the retina morphologically and functionally;  (2) intraocular surgery in the 80 
study eye(s) within 90 days prior to any eligible visit; (3) current or previous participation in a 81 
clinical trial to treat STGD1; and (4) current participation in, or participation within the last 82 
six months in, any drug trial. 83 
 84 
Prior to data collection, site investigators and study coordinators received training from the 85 
data coordinating center (DCC) in chart review, reporting of VA, and in data entry using the 86 
REDCap (Research Electronic Data Capture) system (http://www.project-87 
redcap.org/cite.php). A standardized clinical report form (CRF), designed by the DCC, was 88 
used at all sites to record information on VA, results from the biomicroscopy of the anterior 89 
segments and dilated fundus examination, and use of vitamin A supplementation at each 90 
study visit. Participant‘s age at enrollment, gender, race and age of symptom onset were 91 
identified from chart review and recorded in a standardized demographic form. For each 92 
participant, data of up to four visits were collected.  93 
 94 
Monocular VA was measured using either Snellen or “Early Treatment of Diabetic 95 
Retinopathy Study (ETDRS)“ charts,11 and the measurements extracted from chart review 96 
were entered into the CRF. A participant may have multiple types of VA captured at a visit, 97 
including best or presenting VA with correction (BPC VA), uncorrected (SC), and pinhole VA. 98 
Up to two types of VA were recorded in the CRF for each eye at each visit. As BPC VA 99 
constituted the major type of VA measurement, all downstream analyses used BPC VA.  100 
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  101 
The retrospective ProgStar study was approved by the Western Institutional Review Board 102 
(WIRB), the local institutional review boards (IRB), and the Human Research Protection 103 
Office (HRPO) of the U.S. Army Medical Research & Materiel Command (USAMRMC). The 104 
study was registered at www.clinicaltrials.gov (Identifier NCT01977846). If required by the 105 
local IRB, participants’ consent was obtained prior to data collection. 106 
 107 
Statistical analysis 108 
Participant demographic and clinical characteristics at the first study visit (baseline visit) 109 
were summarized. Baseline data of study eyes were used to explore the cross-sectional 110 
association of VA with demographics including age ( <=18, >18-50, 50+ years), gender, and 111 
race (white vs. non-white), and clinical characteristics including age at symptom onset (≤14, 112 
15-20, 21-30, 30+) and duration of symptoms (0-2, >2-6, >6-11.5 and >11.5-53 years).  113 
 114 
VA measures were converted to LogMAR scale, and univariate linear models with 115 
generalized estimating equations (GEE) were used to estimate the unadjusted cross-116 
sectional associations while accounting for between-eye correlation, followed by 117 
multivariate linear models with GEE to estimate the adjusted associations adjusting for 118 
variables associated with VA in univariate analyses with p<0.1. Additionally, the variables of 119 
baseline age, and age of onset and duration, were also modeled as continuous variables. 120 
   121 
Linear mixed effects model (LMM) was used on the longitudinal data to estimate the yearly 122 
change rate of VA as described in the supplemental material (available at 123 
www.aaojournal.org). To further identify baseline variables associated with VA change rate, 124 
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LMMs were used by including each variable and its interaction with time. Baseline variables 125 
examined included the aforementioned demographics and clinical characteristics, with 126 
baseline VA also categorized on the basis of WHO’s International Classification of Diseases 127 
(ICD)-10,10, 12 as (i) VA better than or equal to 20/25 (LogMAR≤ 0.1) (i.e. no visual impairment 128 
[VI]); (ii) worse than 20/25 to 20/70 (LogMAR 0.1-0.54) (i.e. mild VI); (iii) worse than 20/70 to 129 
20/200 (LogMAR 0.54-1.0) (i.e. moderate VI); (iv) worse than 20/200 to 20/400 (LogMAR 1.0-130 
1.3) (i.e. severe VI); and (v) worse than 20/400 (LogMAR>1.3)  (i.e. blindness). The univariate 131 
association of each variable with VA change rate was first estimated. As VA progression rate 132 
was shown to differ significantly by baseline VA, adjusted associations were also estimated 133 
using multivariate LMMs including variables that were significantly associated with baseline 134 
VA at p<0.1. 135 
 136 
All analyses were conducted in SAS 9.3, and two-sided p-values from Wald-tests were 137 
reported. For the cross-sectional analysis using GEE models, model fit was assessed using 138 
aggregated residuals,13 and for the longitudinal analysis using LMMs, model fit was assessed 139 
using plots of scaled residuals.  140 
 141 
Results 142 
Among the 251 participants enrolled in the retrospective ProgStar study, 176 participants 143 
with 332 study eyes had BPC VA measurements available for at least two visits and thereby  144 
constituted the study sample (Figure 1).  There were 165 participants (94%) with at least two 145 
likely disease-causing variants in ABCA4 (23/165 had three, and 4/165 had four disease-146 
causing mutations). The remaining 11 participants had one likely disease-causing variant 147 
detected. The median duration of observation was 3.6 years (interquartile range [IQR] 2.7-148 
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5.1 years), and each participant contributed data for 2 to 4 visits (Figure 1).  149 
 150 
Table 1 summarizes the baseline demographic and clinical characteristics of these 151 
participants and the study eyes. There were 109 females (61.9%), and the majority of 152 
participants were white (71.6%). At baseline, the median age was 29.5 (IQR 20-42) years. 153 
Among participants whose age of symptom onset was available (N=140), median age of 154 
onset was 20 (IQR 14-30) years. The median duration from the age of onset to the baseline 155 
visit was 6 (IQR 2-11.5) years.  The median Snellen VA at baseline was 20/115 and LogMAR 156 
was 0.76 (IQR 0.40-1.00), ranging from -0.10 to 1.40. Based on the categorized BPC VA, 53 157 
eyes (16.1%) had no impairment, 65 eyes (19.7%) had mild impairment, 163 (49.4%) eyes 158 
had moderate impairment, and 49 eyes (14.8%) had severe impairment or were blind (Table 159 
1 and Figure 2). Details of the excluded participants and comparisons with the included are 160 
provided in supplemental table 1 (available at www.aaojournal.org). 161 
 162 
Cross-sectional associations of participant characteristics with baseline visual acuity 163 
Table 2 presents the baseline VA in subgroups determined by participant characteristics and 164 
the difference of VA between subgroups. When age was modeled as a continuous variable, 165 
worsening VA was significantly associated with older age (adjusted VA LogMAR difference 166 
with every 5 years older in age: 0.04, 95%CI [0.01, 0.07], p=0.006); suggesting that the 167 
observation of worse VA associated with younger age in univariate analysis was mainly 168 
explained by earlier symptom onset in younger participants. 169 
 170 
Figures 3A and 3B show the distribution of baseline VA by quartiles of age at onset and 171 
duration of symptoms respectively. Later symptom onset was associated with better VA in 172 
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both univariate and multivariate analyses (Table 2): compared to patients with onset age 173 
≤14 years and after adjusting for duration since symptom onset, both patients with onset 174 
age >30 years had ~2.3 lines better VA (LogMAR adjusted difference -0.23, 95%CI -0.39, -175 
0.06, p=0.007), and patients with onset age of 21-30 years had 1.1 lines better VA (LogMAR 176 
difference -0.11, 95%CI -0.25, 0.03, p=0.12). Longer duration since symptom onset was 177 
associated with worse VA: after adjusting for age of onset, patients who had symptoms for 178 
6-11.5 years and patients with symptoms for over 11.5 years both had 1.8 lines worse VA 179 
(LogMAR difference 0.18, 95%CI 0.03, 0.33, p=0.002, and difference 0.18, 95%CI 0.02, 0.33, 180 
p=0.03, respectively) compared to patients with recent onset (duration ≤2years) (Table 2).  181 
 182 
Longitudinal analysis of yearly change in visual acuity and associated risk factors 183 
The overall yearly rate of VA change was ~0.3 lines worsening per year; LogMAR change of 184 
0.03, 95%CI (0.026, 0.043; p<0.0001) per year. Table 3 shows the yearly VA change rate by 185 
subgroups and the differences between subgroups. The baseline VA level was significantly 186 
associated with yearly rate of VA change: (i) VA of eyes with no impairment worsened at a 187 
rate of ~1.0 line (LogMAR rate 0.096, 95%CI [0.080, 0.112]) per year; (ii) eyes with mild 188 
impairment worsened at a rate of ~0.9 lines (LogMAR rate 0.094, 95%CI [0.080, 0.107]) per 189 
year; and (iii) VA of eyes with moderate impairment worsened at a rate of 0.2 lines (LogMAR 190 
rate 0.019, 95%CI [0.008, 0.029]) per year. For eyes with severe impairment or blindness at 191 
baseline, their VA improved at an annual rate of 0.5 lines (LogMAR rate -0.047, 95%CI [-192 
0.064, -0.031]) per year.  Figure 4 shows the estimated average rates of change in these 193 
subgroups (Spaghetti plots are provided as Supplemental Figure 1, available at 194 
http://www.aaojournal.org). When comparing the annual VA change between different 195 
baseline VA groups, there were significant differences in both univariate and multivariate 196 
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analyses: the adjusted LogMAR difference in yearly VA change rate was -0.08 (95%CI [-0.11,-197 
0.06], p<.0001) between eyes with moderate impairment and eyes with no impairment, and 198 
was -0.16 (95%CI [-0.19,-0.12], p<.0001) between eyes with severe impairment / blindness 199 
and eyes with no impairment. However, the VA loss rate was not significantly different 200 
between eyes with mild and no impairment.  201 
 202 
Age of symptom onset was not associated with VA change in univariate analysis (Table 3).  203 
However, in the multivariate analysis that adjusted for baseline VA and symptom duration, 204 
compared to patients with age of onset ≤14 years, participants with symptom onset age >30 205 
years had a significant 0.4 lines slower change of VA per year (LogMAR difference -0.04, 206 
95%CI [-0.07, -0.01] per year, p=0.01). When age of onset was modeled as a continuous 207 
variable, every 5 years later in symptom onset was also associated with a significantly slower 208 
VA loss (i.e. difference in LogMAR VA change rate=-0.006, 95%CI [-0.01, -0.002] per year, 209 
p=0.005).  210 
  211 
Longer symptom duration was significantly associated with slower VA worsening in 212 
univariate analysis (Table 3). After adjusting for baseline VA and age of onset, duration was 213 
no longer associated with VA change (Table 3).  214 
 215 
Discussion 216 
We have characterized the demographic and clinical characteristics and VA of a cohort of 217 
STGD1 patients enrolled from the US and Europe in the ProgStar retrospective study. Half of 218 
the participants reported onset of symptoms at age of 30 years or older, i.e. adult-onset 219 
STGD1.  220 
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 221 
In our study, over 35% of the study eyes had no or mild visual impairment at baseline, with 222 
the average BPC VA being better than that of participants enrolled in prior studies.7, 9, 14 223 
Nevertheless, as reported in these studies, our cross-sectional analysis also showed that a 224 
younger age of symptom onset was associated with worse VA. Additionally, as reported in 225 
Testa et al., we found that a longer duration of onset was associated with worse VA.9  Older 226 
age groups had better VA, which was also observed in Rotenstreich et al.7 Considering 227 
younger participants have earlier symptom onset, after adjusting for age of onset, our 228 
multivariate analysis showed that older age was associated with worse VA, which is 229 
compatible with our finding that longer duration since symptom onset was associated with 230 
poorer VA. 231 
  232 
Our longitudinal analysis estimated a 0.3 line loss of BPC VA per year overall. A similar rate of 233 
VA change can be inferred from the survival analysis by Rotenstreich et al.7 that reported a 234 
median time of 22 years from VA of 20/40 or better to reach VA of 20/200 or worse (i.e. ~7 235 
lines loss in 22 years). For the group of participants with symptom onset age <30 years, we 236 
estimated the rate of VA loss to be ~ 0. 4 lines per year. The same rate was also reported in 237 
the recent study by Testa et al.9  that focused on patients with age of onset <30 years. 238 
 239 
We found the better the baseline VA, the faster decline over time: VA of eyes starting with 240 
no or mild impairment declined one line per year, and VA of eyes with moderate impairment 241 
declined at a significantly slower rate. Counterintuitively, eyes that already had VA worse 242 
than 20/200 at baseline showed a small but statistically significant improvement in VA over 243 
time. This may relate to the poor inherent accuracy of Snellen charts in measuring low 244 
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vision15 Other reasons include a lack of standardization in illumination, correction for 245 
refractive errors, and contrast in the tests that generated our VA data. However, there is 246 
also a biological plausibility for observing improvement in VA, as a result of change of the 247 
fixation location of the preferred retinal locus (PRL). 16-19  This phenomenon of eccentric 248 
fixation and its better use by the patient over time is currently an area of interest for on-249 
going research, especially in the context with reading rehabilitation.20 In the case of STGD1, 250 
it is also possible for the PRL to move from a superior retinal locus to the peripapillary region 251 
as the central scotoma expands with disease progression.21 Another possible explanation 252 
might be the statistical phenomenon of “regression towards the mean” that describes the 253 
observation of outliers being more likely to retest closer to their mean values. 22  254 
 255 
In keeping with previous findings, after controlling for baseline VA level, younger age of 256 
symptom onset was associated with faster loss of VA.7  257 
Our data may have implications on selection of appropriate outcome measures for future 258 
STGD1 clinical trials. VA is an important visual function outcome directly related to 259 
participants daily activities,23 and is the most common primary outcome measure for 260 
efficacy studies of retinal diseases.24 Changes of at least 15 ETDRS letters are considered 261 
clinically significant.24 Our study showed that the overall rate of VA decline was slow, thus 262 
VA is not sensitive enough to show a clinically relevant change during a treatment trial. 263 
However, we found that for the subgroup of participants with no or mild visual impairment 264 
(35% of the cohort), the VA loss rate was approximately 1 line per year; suggesting that in a 265 
trial with three to four years of follow-up a clinically significant change may be anticipated in 266 
such participants. Hence a therapy shown to be efficacious in slowing VA deterioration in 267 
this population may potentially benefit a significant number of patients with STGD1. One 268 
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limitation of this finding is that it only alludes to patients enrolled into this retrospective 269 
study who by definition have shown some degree of progression in the past..   270 
 271 
Our study herein has further limitations. First, data were collected through retrospective 272 
review of medical records, thus VA was not measured in a standardized way over time 273 
within the same clinic and across the different study sites. Second, our longitudinal analysis 274 
used repeatedly measured best-corrected or presenting VA. As chart review often could not 275 
differentiate between best corrected VA and presenting VA, it was possible that the change 276 
observed in a participant was due to change in refraction rather than due to disease 277 
progression. Third, BPC VA was not consistently available in all participants, and only 70% 278 
had multiple visits with BPC VA data available. Comparison between participants included in 279 
and those excluded from this analysis showed comparable distributions of most participant 280 
characteristics, but there was difference in race composition and vitamin A use status (see 281 
supplemental table 1, available at www.aaojournal.org).  However, such differences are 282 
unlikely to have biased the results as race and vitamin A use was not found to be associated 283 
with VA change. Lastly, information on age of symptom onset could not be retrieved for 18% 284 
of participants. However, comparisons between participants with known and those with 285 
unknown age of onset did not show significant differences in their demographics and 286 
baseline VA distributions (data not shown), thus the results regarding age of onset using 287 
available data should not have been biased.  288 
 289 
Strengths of our study include that we assessed the associations of VA with a range of 290 
variables on demographics and clinical characteristics, some of which have not been 291 
explored previously. Additionally, our study participants were enrolled from multiple sites in 292 
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the US and Europe, increasing the generalizability of our findings. Lastly, despite being a 293 
retrospective study, data abstraction and entry was conducted in a standardized way by 294 
trained study coordinators, and the data coordinating center’s monitoring visits at the 295 
participating sites ensured the data quality.  296 
In conclusion, we identified that the rate of VA loss in the entire cohort was too slow to be 297 
an effective clinical trial outcome measure. However, a faster decline in younger patients 298 
and those with no or mild visual impairment at baseline, suggests that VA may be a potential 299 
end-point in these patient subgroups, and is worthy of assessment in the prospective study 300 
bearing in mind the inherent biases of retrospective data. It is also important to explore 301 
other potentially more sensitive outcome measures based on imaging modalities or 302 
psychophysical tests, such as spectral-domain optical coherence tomography25 or 303 
microperimetry.26 304 
305 
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Figure legends: 373 
Figure 1: Flowchart of the study participants 374 
Figure 2: Illustrative examples of eyes with no impairment (A: best-corrected or presenting 375 
visual acuity (BCP-VA 20/16), mild impairment (B: BCP-VA 20/32), moderate impairment (C: 376 
BCP-VA 20/120), and severe impairment or blindness (D: 20/400) according to WHO-criteria. 377 
 378 
Figure 3A: Best-corrected or presenting visual acuity at baseline by quartiles of age of 379 
symptom onset. 380 
 381 
Figure 3B:  Best-corrected or presenting visual acuity at baseline by quartiles of duration of 382 
symptoms.  383 
 384 
Figure 4. Estimated average rate of change of visual acuity and its 95% confidence interval, 385 
by baseline visual acuity. (VI: visual impairment) 386 
 387 
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